Navigation

Arrythmias - ICDs & Heart failure - cardiac resynchronisation [ID481]

Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120)

Status: In development
Expected date of issue: June 2014
Process: MTA
Topic area:
  • Cardiovascular
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Anwar Jilani
Communications manager: Phil Ranson
Project manager:

Jeremy Powell

Top


 

Provisional schedule

Consultation on draft scope by stakeholders: 1st draft scope - 21 April 2011
2nd draft scope - 12 July 2011
Closing date for invited submissions / evidence submission: 6 July 2012
1st appraisal committee meeting: 23 April 2013
2nd appraisal committee meeting: 20 November 2013
3rd appraisal committee meeting: 19 March 2014
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Biotronik UK
  • Boston Scientifi
  • Medtronic UK
  • Sorin Group
  • St Jude Medical UK

Patient/carer groups

  • Arrhythmia Alliance
  • SADS UK

Professional groups

  • British Association for Nursing in Cardiovascular Care
  • British Cardiovascular Society
  • British Heart Foundation
  • Heart Rhythm UK
  • Primary Care Cardiovascular Society
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Assembly Government

General

  • Association of British Healthcare Industries
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Comparator manufacturers

  • Actavis UK (amiodarone, bendroflumethiazide, diltiazem felodipine, fosinopril, furosemide, lisinopril, nevibolol, perindorpil, ramipril, trandolapril verapamil)
  • Alliance Pharmaceuticals (Acenocoumarol, Chlortalidone)  (not participating)
  • Bayer (nifedipine, nimodipine)  (not participating)
  • Kent Pharmaceuticals(amiodarone)  (not participating)
  • LEO Laboratories (bumetanide)  (not participating)
  • Novartis Pharmaceutical UK(isradipine)  (not participating)
  • Roche (carvedilol cilazapril)  (not participating)
  • Sandoz (bisoprolol)  (not participating)
  • Sanofi Aventis (amiodarone, diltiazem metolazone)  (not participating)
  • Sigma Pharmaceuticals (amiodarone)  (not participating)
  • Teva UK (amiodarone)  (not participating)
  • UCB Pharma UK (moexipril, nifedipine)  (not participating)
  • Winthrop Pharmaceuticals UK (amlodipine, cilazapril, ramipril, indapamide)  (not participating)
  • Wockhardt UK (amiodarone, furosemide)  (not participating)

Relevant research groups

  • None

Assessment Group

  • Southampton Health Technology Assessment Centre
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Clinical Guideline Centre

Associated Public Health Groups

  • Tbc

Top


 

Project history

Date Update
13 June 2013 Following the meeting of the NICE Technology Appraisal Committee on 23 April the Committee decided to seek additional analyses. No Appraisal Consultation Document (ACD) will be issued at this stage. We issue details of the next steps in this appraisal once these are confirmed.
29 December 2011 Due to the complexity of the issues in this review of two pieces of existing NICE guidance this appraisal will run to extended timelines.
27 July 2011

Following the scoping workshop on 7 June 2011, it was felt that it would be helpful to invite comments on the revised scope produced following the workshop.

The deadline for comments on the draft scope is 9 August 2011.

 

Top


 

Key documents

This page was last updated: 10 February 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.